Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C

Therapeutic Drug Monitoring

Volumn 22, Issue 5, 2000, Pages 555-565

  Jen, J Frank ^a   Glue, Paul ^a   Gupta, Samir ^a   Zambas, Demetris ^a   Hajian, Gerald ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chronic hepatitis C; Population pharmacokinetics and pharmacodynamics; Ribavirin

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CREATININE; HEMOGLOBIN; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIMICROBIAL THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0033806292     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200010000-00010     Document Type: Article

References (23)

1. Ribavirin: An antiviral agent
2. Ribavirin as therapy for chronic hepatitis C
3. Interferon alfa-2b alone or in combination with ribavirin for treatment of relapse of chronic hepatitis C
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C
5. Ribavirin and interferon alpha-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions
6. Ribavirin uptake by human erythrocytes is mediated by es nucleoside transporters
7. Comparison of approaches in population pharmacokinetic analysis of concentrations at steady state
8. Assessment of hematological effects of ribavirin in humans
9. National Institutes of Health Consensus Development conference panel statement: Management of hepatitis C
10. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients
11. Prediction of creatinine clearance from serum creatinine
12. The clinical pharmacology of ribavirin
13. Age-related response to interferon alfa treatment in women versus men with chronic hepatitis C virus infection
14. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus
15. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C
16. Significance of serum hepatitis C virus RNA in chronic hepatitis C
17. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon α 2a therapy
18. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV positive chronic active hepatitis
19. Interferon therapy for patients more than 60 years of age with chronic hepatitis C
20. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C
21. Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients
22. A pilot study of ribavirin therapy for chronic hepatitis C